Appointed to this role in October 2023, Al Reba oversees US commercial efforts for the blockbuster medicine Eliquis, which is the leading cardiovascular product in the world, helping over 32 million patients; the recently launched Camzyos, which is the first and only medicine of its kind to target symptomatic obstructive hypertrophic cardiomyopathy at its source; and the company's established brands portfolio. Mr. Reba also serves as the site lead for our Princeton Pike office.

Reba has been with BMS since 1999, taking on roles of increasing leadership within the organization across multiple therapeutic areas, including cardiovascular, neuroscience, metabolics, and oncology. Notably, his previous BMS experience includes serving as the US launch lead for Eliquis (2008 - 2014), the General Manager of BMS Canada (2017 - 2020), and the Senior Vice President of Worldwide Cardiovascular and Established Brands (2021 - 2023). Prior to BMS, Reba worked with Andersen Consulting as an information technology and strategy consultant.

Reba earned his BS in Industrial Engineering and Operations Research from Cornell University, and holds an MBA from the University of Michigan Business School. He currently lives in Montgomery, NJ, with his wife Judy andtheir three children, Caitlyn, Ethan, and Jack.